Partnering to Advance Precision Genetic Medicine Delivery
Dawn Therapeutics is a preclinical biotechnology company developing a dual-platform delivery strategy for genetic medicines, combining a stealth lentiviral platform (sLV) and a targeted lipid nanoparticle platform (iLNP). We work with partners to accelerate programme development, improve tissue targeting, and build translationally disciplined paths toward CTA/IND readiness.
Why Partner with Dawn Therapeutics?
Our mission depends on high-quality collaboration. Dawn offers partners a focused preclinical platform company with differentiated tissue-targeting capabilities, milestone-based development planning, and flexible partnership structures across licensing, co-development, translational execution, and future programme expansion.
Precision delivery for difficult tissues
Dawn combines an immune-stealth lentiviral platform with a tissue-targeted LNP platform to enable precise in vivo delivery to CNS, cartilage, joints, and liver, with a strong focus on indications where conventional delivery approaches struggle.
Preclinical platform performance with translational relevance
Dawn’s non-clinical datasets support tissue-targeting performance in joints, cartilage, and BBB-relevant models, including joint/cartilage expression and knockdown signals, and strong brain exposure metrics in TfR-targeting studies. These data support scientific discussions for licensing and co-development, while all programmes remain investigational.
Flexible partnership models across a scalable platform strategy
Dawn is structured for multiple non-competing collaborations, including platform licensing, indication-specific co-development, translational collaborations, and strategic alliances. This enables partners to access Dawn’s delivery technologies in defined fields, territories, or disease areas beyond core internal programmes.
Partner-ready execution, with IP and regulatory groundwork
Dawn’s partner framework is supported by a defined 24-month preclinical-to-CTA/IND readiness plan, formal Go/No-Go gates, external delivery partners (including Virocell, Pharmidex, and CGT Catapult), and an active IP/FTO strategy to support collaboration planning and due diligence.
Our Partnership Models
Dawn Therapeutics is a preclinical biotech, and all programmes are investigational. We recognise that every collaboration is unique, so we offer multiple partnership routes across platform licensing, programme development, translational execution, and patient-centred innovation.
1. Co-Development Partnerships
Partner with Dawn to co-develop selected programmes, particularly new applications of our delivery platforms, with shared development costs, milestones, and commercial rights designed around the needs of each indication.
2. Platform Licensing Agreements
License Dawn’s proprietary delivery technologies, including our stealth lentiviral vector (sLV) and targeted iLNP platforms, for defined fields, territories, or indications outside our core internal focus.
3. Research & Translational Collaborations
Work with Dawn and our academic translational network to advance target selection, payload optimisation, tissue targeting, and preclinical validation for gene and RNA programmes in high-need disease areas.
4. Manufacturing & CMC Partnerships
Collaborate with Dawn on a staged manufacturing and CMC pathway, from partner-led GMP production in the near term to a hybrid model as programmes mature, enabling efficient scale-up with strong quality oversight.
5. Preclinical Safety & Regulatory Partnerships
Join us in accelerating CTA/IND readiness through specialist toxicology, regulatory, and development support, including study design, CMC gap analysis, agency engagement, and milestone-based programme planning.
6. Patient & Healthcare System Partnerships
Collaborate with patient organisations and healthcare system stakeholders to support trial readiness, evidence generation, and early access planning, while keeping patient-centred development at the heart of every programme.
Areas of Interest
We are especially interested in partnerships for:
We are especially interested in partnerships for:
- Lysosomal Storage Diseases
- Rare Genetic Disorders
- Musculoskeletal disorders
- Orphan and ultra-orphan indications with high unmet need
- Platform technology enhancements (capsid engineering, LNP optimisation, RNA chemistry)
Why collaborate with Dawn Therapeutics?
- Scientific Excellence – Experienced team with expertise spanning molecular biology, bioinformatics, translational medicine, and regulatory affairs.
- Regulatory Insight – Global regulatory engagement experience, including FDA, EMA, MHRA.
- Speed to Clinic – Integrated design–make–test–learn cycle to shorten timelines.
Shared Vision – Patient-centric approach embedded in every programme
How to Engage
1
2
3
Formal due diligence and partnership structuring.
4
Partnership Portal
Thank you for your interest in partnering with Dawn Therapeutics. Please complete the form below so our team can review your proposal efficiently. This portal is intended for scientific, strategic, translational, and patient-centred partnership enquiries.
